Next-generation vaccine platforms must be ready to respond within weeks to new threats.
open
Global / Unspecified, Global
WS02038
mRNA and vector-based technologies can shorten response times, but manufacturing capacity and regulatory agility must be built in advance. Global manufacturing networks and adaptive trial designs will matter.